Asymchem Laboratories (Tianjin) Co., Ltd. (HKG:6821)

Market Cap	39.79B +32.4%
Revenue (ttm)	6.88B +12.8%
Net Income	1.14B +35.1%
EPS	3.13 +32.4%
Shares Out	n/a
PE Ratio	35.04
Forward PE	25.77
Dividend	1.20 (1.59%)
Ex-Dividend Date	Jun 25, 2025

Volume	405,720
Average Volume	277,321
Open	75.75
Previous Close	75.75
Day's Range	75.10 - 80.60
52-Week Range	39.95 - 116.60
Beta	0.23
RSI	51.41
Earnings Date	Mar 30, 2026

About HKG:6821

Asymchem Laboratories (Tianjin) Co., Ltd. provides clinical stage CDMO, commercial stage CDMO, and emerging services in Mainland China and internationally. The company offers API solutions, such as small molecules, highly potent, carbapenems, glycans, peptides, oligonucleotides, and therapeutic enzymes; GMP, non-GMP, asymchem lab facilities and capabilities, commercial manufacturing, clinical manufacturing, separations, crystallization, fermentation, continuous FlowGMP, non-GMP, Asymchem lab facilities and capabilities, commercial manufacturing...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 9,595
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6821

Financial Performance

In 2024, HKG:6821's revenue was 5.80 billion, a decrease of -25.82% compared to the previous year's 7.83 billion. Earnings were 948.95 million, a decrease of -58.17%.

Financial numbers in CNY